Anchyra Partners LLC Buys Shares of 3,001 AstraZeneca PLC $AZNCF

Anchyra Partners LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, Holdings Channel.com reports. The firm purchased 3,001 shares of the company’s stock, valued at approximately $592,000.

A number of other large investors have also recently made changes to their positions in AZNCF. Saranac Partners Ltd bought a new stake in AstraZeneca in the 3rd quarter worth approximately $876,000. Mascoma Wealth Management LLC purchased a new position in shares of AstraZeneca in the 4th quarter worth $46,000. Valley Wealth Managers Inc. purchased a new position in shares of AstraZeneca in the 4th quarter worth $144,000. Hendley & Co. Inc. bought a new stake in shares of AstraZeneca in the fourth quarter worth $11,373,000. Finally, L & S Advisors Inc bought a new stake in shares of AstraZeneca in the fourth quarter worth $14,863,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock opened at $187.10 on Tuesday. The stock has a fifty day moving average of $187.10 and a 200 day moving average of $186.10. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.